Cytek reaffirms $196M-$205M 2025 revenue outlook as recurring businesses accelerate
Source: SeekingAlpha
2025-11-05 20:51:53 ET
More on Cytek Biosciences
- Cytek Biosciences, Inc. (CTKB) Q3 2025 Earnings Call Transcript
- Cytek Biosciences, Inc. (CTKB) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)
- Cytek Biosciences: Growth Over Profit Will Pay Off In The Long Term
- Seeking Alpha’s Quant Rating on Cytek Biosciences
- Historical earnings data for Cytek Biosciences
Read the full article on Seeking Alpha
For further details see:
Cytek reaffirms $196M–$205M 2025 revenue outlook as recurring businesses accelerate
Cytek Biosciences Inc.
NASDAQ: CTKB
CTKB Trading
0.11% G/L:
$4.53 Last:
436,531 Volume:
$4.38 Open:
CTKB Latest News
March 09, 2026 05:00:00 pm
Cytek® Biosciences Celebrates One Year of Operations at Singapore Facility, Accelerating Growth and Regional Impact
February 26, 2026 04:05:00 pm
Cytek Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Outlook
CTKB Stock Data
$553,654,714
114,656,393
9.13%
48
N/A
Biotechnology & Life Sciences
Healthcare
US
Fremont
